Artemis Investment Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$227M Buy
1,041,483
+337,485
+48% +$74.9M 2.4% 3
2025
Q4
$161M Sell
703,998
-78,703
-10% -$17.9M 1.94% 5
2025
Q3
$181M Buy
782,701
+104,105
+15% +$21.2M 2.26% 5
2025
Q2
$126M Buy
678,596
+111,836
+20% +$20.8M 1.61% 11
2025
Q1
$119M Buy
566,760
+82,933
+17% +$16.1M 1.82% 8
2024
Q4
$86M Buy
483,827
+417,839
+633% +$76.8M 1.22% 21
2024
Q3
$13M Sell
65,988
-267,300
-80% -$49.9M 0.2% 122
2024
Q2
$57.2M Sell
333,288
-119,365
-26% -$19.8M 0.77% 38
2024
Q1
$82.4M Buy
452,653
+14,963
+3% +$2.58M 1.04% 23
2023
Q4
$67.8M Buy
437,690
+49,595
+13% +$7.23M 0.98% 27
2023
Q3
$57.8M Buy
388,095
+86,638
+29% +$12.7M 0.81% 38
2023
Q2
$40.6M Sell
301,457
-217,383
-42% -$31.9M 0.51% 60
2023
Q1
$82.5M Buy
518,840
+61,560
+13% +$9.41M 1.01% 29
2022
Q4
$74.3M Buy
457,280
+81,372
+22% +$12.5M 0.84% 44
2022
Q3
$50.5M Sell
375,908
-124,363
-25% -$17.8M 0.58% 59
2022
Q2
$77M Buy
500,271
+20,218
+4% +$3.09M 0.79% 42
2022
Q1
$77.7M Buy
480,053
+80,630
+20% +$11.7M 0.62% 45
2021
Q4
$54M Buy
399,423
+26,035
+7% +$3.08M 0.39% 83
2021
Q3
$40.2M Sell
373,388
-58,363
-14% -$6.67M 0.32% 92
2021
Q2
$48.7M Sell
431,751
-190,500
-31% -$21.5M 0.42% 69
2021
Q1
$67.3M Sell
622,251
-104,740
-14% -$11.2M 0.64% 44
2020
Q4
$77.9M Buy
726,991
+264,440
+57% +$25.4M 0.81% 32
2020
Q3
$40.5M Sell
462,551
-150,184
-25% -$14.1M 0.51% 56
2020
Q2
$60.3M Sell
612,735
-311,437
-34% -$27.4M 0.81% 31
2020
Q1
$70.4K Sell
924,172
-116,413
-11% -$9.92M 0.12% 24
2019
Q4
$92M Buy
1,040,585
+153,561
+17% +$12.7M 1.16% 18
2019
Q3
$67M Sell
887,024
-263,288
-23% -$18.1M 0.92% 29
2019
Q2
$83.4M Buy
1,150,312
+178,180
+18% +$14M 0.99% 27
2019
Q1
$78.4M Sell
972,132
-885,786
-48% -$72.5M 0.91% 33
2018
Q4
$171M Buy
1,857,918
+94,632
+5% +$8.32M 2.23% 2
2018
Q3
$167M Sell
1,763,286
-175,461
-9% -$16.6M 1.85% 7
2018
Q2
$180M Buy
1,938,747
+97,936
+5% +$9.56M 2.45% 5
2018
Q1
$174M Buy
1,840,811
+189,661
+11% +$20.8M 2.7% 2
2017
Q4
$160M Buy
1,651,150
+303,329
+23% +$28.6M 2.66% 6
2017
Q3
$120M Buy
1,347,821
+291,987
+28% +$22.2M 2.46% 4
2017
Q2
$76.5M Buy
1,055,834
+365,259
+53% +$24.6M 1.86% 9
2017
Q1
$45M Buy
690,575
+196,859
+40% +$12.4M 1.21% 23
2016
Q4
$30.9M Sell
493,716
-265,011
-35% -$16.2M 0.83% 27
2016
Q3
$47.8M Sell
758,727
-748,689
-50% -$48.5M 1.34% 15
2016
Q2
$93.3M Sell
1,507,416
-503,456
-25% -$30.7M 2.54% 5
2016
Q1
$115M Buy
2,010,872
+400,085
+25% +$22.3M 2.89% 5
2015
Q4
$95.4M Sell
1,610,787
-27,896
-2% -$1.61M 2.39% 5
2015
Q3
$89.1M Sell
1,638,683
-354,472
-18% -$23.1M 2.63% 6
2015
Q2
$134M Buy
1,993,155
+1,043,121
+110% +$68.1M 4.34% 4
2015
Q1
$55.6M Sell
950,034
-650,596
-41% -$39.3M 2.22% 7
2014
Q4
$105M Buy
1,600,630
+98,607
+7% +$6.22M 4.07% 3
2014
Q3
$86.8M Buy
+1,502,023
New +$83.4M 4.35% 1

Other funds holding ABBV

Artemis Investment Management's ABBV Position: Q1 2026 in Review

Artemis Investment Management increased its AbbVie (ABBV) stake by 48% in Q1 2026, buying an estimated $74.9M and bringing the position to 1,041,483 shares worth $227M. The position accounts for 2.4% of the portfolio, ranked #3.

Artemis Investment Management first reported a position in ABBV in Q3 2014 and has held it in 47 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Artemis Investment Management held 1,041,483 shares of AbbVie worth $227M as of Q1 2026.
  • Artemis Investment Management bought 337,485 AbbVie shares in Q1 2026, an estimated $74.9M.
  • AbbVie made up 2.4% of Artemis Investment Management's portfolio in Q1 2026, its #3 holding.
  • Artemis Investment Management first reported a position in AbbVie in Q3 2014 and has held it in 47 quarters since.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Artemis Investment Management's 13F filing for Q1 2026, filed 13 Apr 2026.